Barbic, Skye P.
Jones, Andrea A.
Woodward, Melissa
Piercy, Matt
Mathias, Steve
Vila-Rodriguez, Fidel
Leonova, Olga
Smith, Geoffrey N.
Buchanan, Tari
Vertinsky, Alexandra T.
Gillingham, Stephanie
Panenka, William J.
Rauscher, Alexander
Barr, Alasdair M.
Procyshyn, Ric M.
MacEwan, G. William
Lang, Donna J.
Thornton, Allen E.
Heran, Manraj K.
Leon, Adelena M.
Krausz, Michael
Honer, William G.
Article History
Received: 20 July 2017
Accepted: 10 January 2018
First Online: 31 May 2018
Compliance with ethical standards
:
: Dr. Vila-Rodriguez has received Advisory Board fees from Janssen. Dr. Panenka is on the board of directors (Abbatis Bioceuticals) or scientific advisory boards (Medipure Pharmaceuticals and Vinergy Inc) of three local emerging biotechnology companies. Dr. Rauscher has received advisory board fees from Hofmann-La Roche. Dr. Barr has received consulting fees or sat on Advisory Boards for Bristol-Myers Squibb, Eli Lilly, and Roche. Dr. Procyshyn has received speaking and Advisory Board fees from Janssen, Lundbeck, and Otsuka. He has also received Royalties as the Principal Editor ofThe Clinical Handbook of Psychotropic Drugs. Dr. MacEwan has received speaking or consulting fees or sat on advisory boards for Apotex, AstraZeneca, Bristol-Myers Squibb, Janssen, Lundbeck, Otsuka, Pfizer, and Sunovion and has received research grant support from Janssen. Dr. Honer has received consulting fees or sat on Advisory Boards for In Silico, Lundbeck, Otsuka, and Alphasights. The remaining authors declare no conflict of interest.